menu
    • menu

    Company profile for Kahr Medical

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    KAHR Medical is developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications KAHR’s proprietary technology, known as DSP (Dual Signaling Proteins), enables the construction of targeted biological drugs with two functional ends, which can simultaneously block and/or activate two reinforcing biological signals resulting in a synergistic outcome. KAHR’s new...
    KAHR Medical is developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications KAHR’s proprietary technology, known as DSP (Dual Signaling Proteins), enables the construction of targeted biological drugs with two functional ends, which can simultaneously block and/or activate two reinforcing biological signals resulting in a synergistic outcome. KAHR’s new DSP platform emerged following years of research and development of TNF-superfamily based drug candidates.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kahr MedicalIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    1 Kiryat Hadassah JBP Bldg. POB 9779 Jerusalem Israel 9109701
    Telephone
    Telephone
    972-73-7969196
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://kahrbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    KAHR and Cancer Focus Fund Begin Dosing in Phase 1b Trial of DSP107
    KAHR and Cancer Focus Fund Begin Dosing in Phase 1b Trial of DSP107

    17 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/kahr-and-cancer-focus-fund-announce-first-patient-dosed-in-phase-1b-clinical-trial-of-anti-cd47-product-candidate-dsp107-in-blood-cancers-301484721.html

    PRNEWSWIRE
    17 Feb 2022
    Share Share
    KAHR Announces $46.5 Million Financing for Immunotherapeutic Pipeline
    KAHR Announces $46.5 Million Financing for Immunotherapeutic Pipeline

    16 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/kahr-announces-46-5-million-financing-to-advance-its-multifunctional-immunotherapeutic-pipeline-301313437.html

    PRNEWSWIRE
    16 Jun 2021
    Share Share
    Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect
    Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect

    16 Jun 2021

    // N. P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/kahr-reels-47m-to-fund-cd47-trial-work-tigit-prospect

    N. P. Taylor FIERCEBIOTECH
    16 Jun 2021
    Share Share
    An Israeli biotech is looking to make its name in the jam-packed CD47 space
    An Israeli biotech is looking to make its name in the jam-packed CD47 space

    16 Jun 2021

    // Nicole DeFeudis ENDPTS

    https://endpts.com/an-israeli-biotech-is-looking-to-make-its-name-in-the-jampacked-cd47-space-is-bifunctionality-the-answer/

    Nicole DeFeudis ENDPTS
    16 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search